{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:29:27Z","timestamp":1771457367867,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.4158\/ep10369.cr","type":"journal-article","created":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T21:01:58Z","timestamp":1297890118000},"page":"e55-e58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Positive Prolactin Response to Bromocriptine in 2 Patients with Cabergoline-Resistant Prolactinomas"],"prefix":"10.1016","volume":"17","author":[{"given":"Pallavi","family":"Iyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Molitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP10369.CR_bb0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group","volume":"331","author":"Webster","year":"1994","journal-title":"N Engl J Med"},{"key":"10.4158\/EP10369.CR_bb0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","article-title":"Dopamine agonists and pituitary tumor shrinkage","volume":"13","author":"Bevan","year":"1992","journal-title":"Endocr Rev"},{"key":"10.4158\/EP10369.CR_bb0020","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: Prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10369.CR_bb0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"10.4158\/EP10369.CR_bb0030","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","article-title":"Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients","volume":"93","author":"Ono","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10369.CR_bb0035","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: A study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP10369.CR_bb0040","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1210\/jc.2008-2244","article-title":"The cabergoline-resistant prolactinoma patient: New challenges","volume":"93","author":"Molitch","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10369.CR_bb0045","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","article-title":"Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP10369.CR_bb0050","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2265.1986.tb01647.x","article-title":"Discordant responses of prolactinoma to two different dopamine agonists","volume":"24","author":"Ahmed","year":"1986","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP10369.CR_bb0055","first-page":"375","article-title":"Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs","volume":"27","author":"Berezin","year":"1991","journal-title":"Isr J Med Sci"},{"key":"10.4158\/EP10369.CR_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2265.1991.tb01731.x","article-title":"Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas","volume":"34","author":"Duranteau","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP10369.CR_bb0065","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000182739","article-title":"The effects of CV205-502 in patients with hyperprolactinaemia intolerant and\/or resistant to bromocriptine","volume":"39","author":"Razzaq","year":"1993","journal-title":"Horm Res"},{"key":"10.4158\/EP10369.CR_bb0070","first-page":"411","article-title":"Efficacy of quinagolide in resistance to dopamine agonists: Results of a multicenter study. Club de l'Hypophyse","volume":"61","author":"Rohmer","year":"2000","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.4158\/EP10369.CR_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/09513599409072452","article-title":"Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine","volume":"8","author":"Merola","year":"1994","journal-title":"Gynecol Endocrinol"},{"key":"10.4158\/EP10369.CR_bb0080","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/eje.0.1350413","article-title":"Prolactinomas resistant to bromocriptine: Long-term efficacy of quinagolide and outcome of pregnancy","volume":"135","author":"Morange","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP10369.CR_bb0085","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1210\/jcem-69-3-500","article-title":"Resistance to bromocriptine in prolactinomas","volume":"69","author":"Pellegrini","year":"1989","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20404392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20404392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/H17805406W12P620.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:53:01Z","timestamp":1761515581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20404392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1530891X20404392"],"URL":"https:\/\/doi.org\/10.4158\/ep10369.cr","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positive Prolactin Response to Bromocriptine in 2 Patients with Cabergoline-Resistant Prolactinomas","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP10369.CR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}